United Therapeutics (UTHR) CEO A Sells $5.2M of Stock

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), sold 9,500 shares on October 9, 2026, in a planned transaction valued at about $5.2 million. The shares were sold at an average price of $544.94 each.

Inside Rothblatt's Trade

This sale is part of a planned strategy, as indicated by the filing. Rothblatt's transaction comes after a series of insider activities where she purchased shares earlier in June 2026. The recent sale reflects her ongoing engagement with the company's stock, which has seen various fluctuations.

Other Institutional Activity in United Therapeutics

Several institutional investors have adjusted their positions in United Therapeutics. Blackrock Inc. reduced its stake by 105,297 shares, holding a total of 5,294,529 shares valued at about $2.8 billion. Avoro Capital Advisors LLC increased its holdings by 147,804 shares, bringing its total to 2,777,777 shares worth approximately $1.5 billion. Meanwhile, Vanguard Portfolio Management LLC cut its shares by 84,359, ending with 1,919,429 shares valued at about $1.0 billion.

United Therapeutics Corporation Stock Up 0.1%

As of October 16, 2026, United Therapeutics shares are trading around $541.98, which is above the 50-day moving average of $514.66 but below the 200-day average of $526.82. The stock is currently 11.1% under its 52-week high of $609.35, indicating some room for growth relative to its peak.

Recent Earnings

United Therapeutics reported trailing twelve-month revenue of approximately $3.15 billion and an earnings per share (EPS) of $27.92. The next earnings report is scheduled for October 28, 2026, which will provide further insights into the company's performance.

Insider Buying and Selling at United Therapeutics Corporation

Martine Rothblatt has been active in trading United Therapeutics shares. Prior to this sale, she purchased 9,500 shares at $135.42 each on June 26 and again on June 29, totaling about $2.6 million in purchases. The recent sale of 9,500 shares at $544.94 reflects a significant change in her position.

Analysts Set New Price Targets

Analysts have been active in updating their ratings for United Therapeutics. On October 8, 2026, RBC Capital maintained an "Outperform" rating with a new price target of $708. This follows a recent upgrade from BTIG, which set a price target of $728 on October 1, 2026. The consensus among analysts is a "buy" recommendation with a mean target price of $656.93.

About United Therapeutics

United Therapeutics Corporation focuses on developing treatments for serious chronic diseases. The company operates in the healthcare sector, specifically within the drug manufacturing industry. Its ongoing efforts aim to meet the medical needs of patients both in the U.S. and internationally.

Bottom Line

Looking ahead, all eyes are on United Therapeutics as it prepares to report earnings on October 28, 2026. Investors will be keen to see how the company navigates the challenges in the healthcare market and whether insider trades like Rothblatt's provide any signals about future performance.